RxDoctor Payments Data

Robert Raspa, MD

Family Medicine · Orange Park, FLNPI 1356333603

Payments from drug & device makers

$1,714in general payments, 2019–2025

Across 86 payments — averaging $19.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$228
  • Merck$223
  • Novo Nordisk$215
  • Amgen$155
  • Pfizer$147
  • GSK$140
  • plus $607 from 10 others

What the payments were for

  • Food & beverage$1,714100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,714 in reported general payments places this provider in the 70th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$135,123
Medicare patients
229
Services billed
1,799

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide48$69,902
FarxigaDapagliflozin Propanediol41$45,972
MounjaroTirzepatide27$29,385
TrulicityDulaglutide16$23,619
EliquisApixaban18$20,260
JardianceEmpagliflozin17$20,027
JanuviaSitagliptin Phosphate17$9,620
Atorvastatin Calcium214$2,646
Famotidine78$1,589
Fluticasone Propionate48$1,185
Rosuvastatin Calcium94$1,135
Gabapentin47$1,062
Duloxetine Hcl50$1,032
Omeprazole42$1,013
Amlodipine Besylate171$998

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$215$69,90248 claims
Lilly USA, LLCMounjaro, Trulicity$116$53,00443 claims
AstraZenecaFarxiga$228$45,97241 claims
PfizerEliquis$147$20,26018 claims
Boehringer IngelheimJardiance$31$20,02717 claims
MerckJanuvia$223$9,62017 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Orange Park

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →